The potential of S-1 for the treatment of metastatic renal cell carcinoma (mRCC) has been shown in two phase II studies. We aimed to assess the safety, tolerance, pharmacokinetics and clinical activity of S-1 combined with sorafenib in patients with mRCC.
introduction
The recent development of novel therapies that target tumor angiogenesis and mammalian target of rapamycin pathways has improved outcomes in patients with advanced renal cell carcinoma (RCC) [1, 2] . Sequential therapy with targeted agents is the current standard of care; however, combination regimens including targeted agents have also been studied to enhance efficacy and combat resistance. Current combination therapy strategies have not been proven to be beneficial, and many combination regimens have shown excessive toxicity with marginal or inferior efficacy compared with that of the sequential-use agents [2] .
We previously reported promising single-agent results for S-1, an oral fluoropyrimidine-based anticancer agent, with an overall response rate (ORR) of 24.4% in patients with cytokinerefractory metastatic RCC (mRCC) at the dose of 80, 100 or 120 mg/day based on body surface area [3] . High sensitivity to S-1 monotherapy was associated low thymidylate synthase (TS) expression in tumors, although myelosuppression was frequently observed. Because molecular targeting agents other than sunitinib rarely cause myelosuppression, S-1 might be a good candidate for combination therapy with molecular targeting agents such as sorafenib.
We therefore assessed the efficacy and safety profile of combination therapy with S-1 and sorafenib in patients with mRCC.
methods
This was a nonrandomized, open-label, multicenter phase I/II trial in Japanese patients with mRCC who had undergone nephrectomy. This trial was conducted in accordance with the World Medical Association Declaration of Helsinki and Japanese Good Clinical Practice guidelines. The protocol was approved by the institutional review boards of all participating institutions. This study is registered with the Japan Pharmaceutical Information Center (number JapicCTI-090973).
eligibility criteria
Patients were eligible if they were 20 years of age or older, and had: a history of nephrectomy; a histologically confirmed diagnosis of clear-cell or papillary RCC; received no previous treatment or only one regimen of cytokine therapy; an Eastern Cooperative Oncology Group performance status of 0 or 1; measurable lesions as defined by the Response Evaluation Criteria in Solid Tumours [4] (RECIST; version 1.0); adequate hematological, hepatic, and renal function. We excluded patients who had brain metastasis, a known hypersensitivity to S-1 or sorafenib, or severe complications, concurrent malignancy, marked pleural effusion or ascites, watery diarrhea or peptic ulcer. Written informed consent was obtained from all patients before enrollment.
study design and treatment
In the phase I portion, we studied four S-1 and sorafenib dose levels. Patients were administered sorafenib orally at a dose of 400 or 800 mg/day. Treatment included S-1 doses, based on body surface area as follows: 60, 80, 100 or 120 mg/day. Dosing levels were as follows: level 0, days 1-28 S-1 60, 80 or 100 mg/day plus days 1-42 sorafenib 400 mg/day; level 1A, days 1-28 S-1 80, 100 or 120 mg/day plus days 1-42 sorafenib 400 mg/day; level 1B, days 1-28 S-1 60, 80 or 100 mg/day plus days 1-42 sorafenib 800 mg/day; and level 2, days 1-28 S-1 80, 100 or 120 mg/day plus days 1-42 sorafenib 800 mg/day (for more detail see supplementary Table S1 , available at Annals of Oncology online). Treatment was administered in 42-day cycles and continued until disease progression, refusal to continue treatment or unacceptable adverse events (AEs). The initially dose administered was level 1B, and dose adjustment then followed a standard three-plus-three design. Given possible interactions between S-1 and sorafenib, a half-dose of sorafenib was used in levels 0 and 1A. If none of the first three patients had dose-limiting toxicity (DLT) during the first cycle, the dose was escalated to level 2. If DLT occurred in one or two of the first three patients given a particular level, then three additional patients were enrolled to receive the same dose level, for a total of six patients. The maximum tolerated dose (MTD) was reached when three or more of six patients at one dose level had DLTs. Thus, this dose was defined as the MTD, and one dose level below was designated as the recommended dose (RD) for phase II. If less than three of the six patients had DLTs at the last dose level, then this dose level was the RD for phase II. If patients less than three of the six had DLTs at the dose level 2, no MTD was determined in this study and the dose level 2 will be fixed as the RD. No intrapatient dose escalation was allowed.
In the phase II portion, patients received combination treatment with S-1 plus sorafenib at the RD determined in the phase I. Treatment was continued until any of the following occurred: unacceptable toxicity, refusal to continue treatment or definite tumor progression. When the predefined toxic events in the protocol occurred, dose adjustment or interruption required (for more detail see supplementary Table S2 , available at Annals of Oncology online).
dose-limiting toxicity
DLT was defined as any of following events occurring during the first cycle of treatment: grade 4 or higher hematological toxicity; grade 3 or higher febrile neutropenia; grade 3 or higher nonhematological toxicity except for hand-foot skin reaction and pancreatic enzyme abnormality; drug-related pancreatitis associated with a grade 4 increase in pancreatic enzymes; AEs requiring suspension of treatment of no <15 consecutive days and AEs requiring discontinuation of treatment.
end points
The primary end point of the phase I portion was the MTD and RD. In the phase II portion, the primary end point was the proportion of patients who had an objective response and confirmed by a subsequent scan. Secondary end points included the safety profile, proportion of patients who achieved disease control [complete response (CR) partial response (PR) or stable disease (SD) maintained for 28 days or longer], progression-free survival (PFS: the time between the initiation of study treatment and disease progression or death from any cause), overall survival (OS: the time between the initiation of study treatment and death from any cause) and pharmacokinetic (PK) parameters.
study evaluations
Tumor imaging was carried out at baseline and at least every 6 weeks thereafter. Complete blood cultures, serum chemical analysis and urinalysis were carried out every week during the first cycle of phase I, followed by every 2 weeks thereafter in phases I and II.
response and toxicity criteria
The RECIST were used to assess the response to treatment, and the Common Terminology Criteria for Adverse Events (version 3.0) [5] were used to assess toxicity. An independent review committee consisting of radiologists and medical oncologists objectively confirmed treatment responses and drug-related AEs.
statistical analysis
In the phase II portion, we initially used a threshold response rate (under the null hypothesis) of 5%, and an expected response rate (under the alternative hypothesis) of 25%, based on the results of two phase II studies of S-1 and a phase II study of sorafenib [3, 6] . Under these assumptions, a sample size of 21 patients would ensure a power of at least 80% at a one-sided significance level of 5%. Thus, a response rate of 4 of 21 patients would permit rejection of the null hypothesis.
We carried out primary analyses on a full analysis set basis; patients who received at least one dose of the assigned study drugs. All analyses were carried out using statistical software package (SAS version 9.2; SAS Institute, Inc., Cary, NC).
pharmacokinetics
In the phase I portion, we obtained blood samples for S-1 PK evaluation at the following time points: pre-dose and 1, 2, 4, 6, 8, 10 and 12 h after co-administration of S-1 and sorafenib on day 1. For sorafenib PK evaluations, blood samples were taken at the following time points: pre-dose and 1, 2, 4, 6, 8 and 12 h after co-administration of S-1 on day 28 and after administration of sorafenib alone on day 35. Plasma samples were prepared by centrifugation of the blood samples. Plasma concentrations of S-1 components original articles
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The C max and AUC 0-12 PK parameters were determined for S-1 components and sorafenib.
results patient characteristics
Between 14 December 2009 and 4 September 2012, a total of 24 patients (9 in phase I and 15 in phase II) were enrolled. All patients were eligible for the toxicity and efficacy evaluation. The first three patients received dose level 1B. The six patients who received dose level 2 during phase I were included in the phase II assessment, along with another 15 patients. The patient characteristics are summarized in Table 1 . There were 34 treatment cycles administered overall (median 15.0, range 2-17) to patients at dose level 1B, and 179 treatment cycles administered overall (median 8.0, range 1-20) to patients at dose level 2. The main reasons for treatment discontinuation at dose levels 1B and 2 were tumor progression in 2 (67%) and 10 patients (48%), respectively, and toxicity in 1 patient (33%) and 5 patients (24%), respectively.
dose-limiting toxicity and recommended dose
All nine patients (three in level 1B and six in level 2) completed at least one cycle and had at least one AE. No patient who was administered dose level 1B had DLT. One DLT (grade 3 stomatitis) occurred in one of the first three patients and one additional patient at level 2 (grade 2 acute hepatitis requiring suspension of treatment of at least 15 consecutive days). Thus, the MTD was not reached in this study. Based on DLT and PK results, the planned highest dose (days 1-28 S-1 80, 100 or 120 mg/day plus days 1-42 sorafenib 800 mg/day) was judged to be acceptable as the RD in the phase II portion.
pharmacokinetics
Blood samples were taken from all nine patients, eight patients were included in the PK analysis on day 1, and seven were available on days 28 and 35. There were also no significant differences in the C max or AUC 0-12 of any of the S-1 components (5-FU, FT, CDHP, Oxo) between the S-1 plus sorafenib combination chemotherapy and S-1 monotherapy [7] [8] [9] [10] (data not shown). At level 1B and level 2, sorafenib plasma concentration-time profiles on day 28 (S-1 and sorafenib co-administration) and day 35 (sorafenib administration alone) were superimposable, with no significant difference in C max or AUC 0-12 (supplementary Table S3 and Figure S4 , available at Annals of Oncology online).
efficacy
A response was evaluated in 24 patients in the phase I and II portions. In the phase I at dose level 1B, one patient (33%) had a PR and two patients (67%) had SD. In the phase II at dose level 2, among the 21 patients, 1 patient (5%) had a CR, 10 patients (48%) had PR and 10 patients (48%) had SD. No patient had progressive disease. Thus, 11 patients [52%, 95% confidence interval (CI) 29.8% to 74.3%] had an objective response, and all patients achieved disease control. The subgroup analyses showed that the ORR was higher in groups with a favorable risk, according to Memorial Sloan-Kettering Cancer Center criteria [11] (supplementary Table S5 , available at Annals of Oncology online). Almost all of patients had a reduction in tumor size compared with baseline ( Figure 1A ). Response to treatment was noted early, and 1 of 11 patients reached PR within 6 weeks, and 6 patients did so within 12 weeks. A total of 16 tumor progression events occurred. The median PFS was 9.9 months (95% CI 6.5-17.1 months, Figure 1B) , and the median OS was not reached (median follow-up, 15.9 months). safety Table 2 lists the documented AEs that were attributable to either drug in all 24 patients study phases I and II. The most frequently reported treatment-related AEs of all grades at dose level 2 were hand-foot skin reaction (100%), hypophosphatemia (95%), anemia (91%), rash (86%), leucopenia (86%), thrombocytopenia (86%), neutropenia (81%), stomatitis (76%), fatigue (71%), anorexia (71%), diarrhea (71%), alopecia (71%), increased lipase (67%), increased amylase (67%) and increased bilirubin (67%). The most frequent grade 3 or higher drug-related AE was hypophosphatemia in 2 (67%) and 16 patients (76%) at dose levels 1B and 2, respectively. A dose reduction of S-1 plus sorafenib combination therapy was needed in 16 patients (76%) who received dose level 2. The major reasons for dose reduction were hand-foot skin reaction in 8 patients (38%) and rash in 3 patients (14%). Dose interruption of both S-1 and sorafenib was required because of hand-foot skin reaction in 8 patients (38%) and because of rash in 5 patients (24%). Serious AEs occurred in two patients (67%) in dose level 1B (grade 4 acute hepatitis and grade 3 knee contusion, and grade 3 total bilirubin elevation) and in three patients (14%) in dose level 2 (grade 2 acute hepatitis, grade 3 hypertension and grade 3 stomatitis). All except for acute cholecystitis and contusion of knee were considered treatment-related toxicities. No deaths occurred during this study.
discussion
This multicenter phase I/II study was initiated to evaluate the efficacy and safety of S-1 plus sorafenib in patients with mRCC. In the present study, S-1 plus sorafenib combination therapy achieved an ORR of 52% and produced a better response than that reported for S-1 or sorafenib monotherapy [3, 6] . The results of our study are supported by the findings of Takeuchi et al., [12] who reported that sorafenib decreased the transcription factor E2F-1 and TS levels in human cell lines in a preclinical study. Recently, several regimens for combination therapy have been studied. However, combination therapy strategies have not been shown to be beneficial, with many combinations showing excessive toxicity and marginal or inferior efficacy compared with the sequential use of agents [2] . S-1 plus sorafenib combination therapy was comparable with standard regimens or interferon plus bevacizumab combination therapy, although we did not directly compare these drugs [2] .
Although S-1 combined with sorafenib achieved a high ORR in our study, the median PFS for S-1 combined with sorafenib as a first-line therapy for mRCC was comparable with that obtained with S-1 or sorafenib [3, 6] . This discrepancy may be attributed to the small number of patients and early dose reduction. To prevent these AEs from worsening, the first dose changes occurred within the first 3 months in a Japanese sorafenib phase II study [6] . In the present study, a similar tendency was seen. Seven patients (33.3%) had their dose reduced within the first 3 months of treatment because of a grade 1 or 2 AE, at the physician's discretion.
S-1 plus sorafenib combination therapy was associated with AEs that are common toxic effects of S-1 or sorafenib [3, 6] . Hand-foot skin reaction, hypophosphatemia and pancreatic enzyme abnormity are common toxicities of sorafenib, and hematological toxicity, rash, stomatitis and diarrhea are common toxicities of S-1. No unexpected toxicities occurred. The different mechanisms of S-1 and sorafenib were considered to be responsible for the lack of overlapping toxicities. This hypothesis is supported by the results of the PK analysis, which established that combined treatment was not associated with any clinically significant alterations in the PK of either S-1 or sorafenib. However, the incidence of hand-foot skin reaction was higher for S-1 plus sorafenib combination therapy than for sorafenib monotherapy or combination therapy with other agents including interferon-α [2, 6, 13] . In addition, the rate of dose reduction was higher than S-1 monotherapy (26.7%), and sorafenib monotherapy (34.4%), although no skin-related serious AE occurred. Our results suggest that skin events management is important in S-1 plus sorafenib combination therapy. Furthermore, compared with other combination therapy regimens, the ability of patients to receive treatment on an outpatient basis is considered an important advantage. Our data showed preliminary efficacy of S-1 plus sorafenib combination therapy in the small number of patients with mRCC. Larger randomized trials are needed to confirm our results.
In conclusion, to our knowledge, this is the first study that showed the efficacy of S-1 in combination with sorafenib as a first-line treatment in patients with mRCC; however, management of toxicity is required.
